drugset / Trial / NCT00932724
CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
Phase 2
Terminated
77 enrolled
Cytavis Biopharma GmbH
Charite University, Berlin, Germany · collabClinAssess · collabMedical University Innsbruck · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on progression free survival (PFS) defined as the time from start of treatment until the objective observation of progressive disease (PD) or death from any course in patients with chemotherapy-refractory metastatic colorectal cancer.
Timeline
- Start
- 2009-07
- Primary completion
- 2012-08
- Completion
- 2012-08
Outcome
Outcome not reported
Stopped (Enrollment): “The sponsor declared the early termination of the study due to poor recruitment of patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aviscumine | Protein / enzyme biologic | 350 ng | Subcutaneous |